Termination of supplies of the drug “Ozempic” in the Russian Federation.

In November 2022, Roszdravnadzor received a notification from the Novo Nordisk manufacturing company about the planned termination of supplies of the Ozempic drug to the Russian Federation.

It should be noted that according to the current legislation of the Russian Federation, the holder of the registration certificate must notify Roszdravnadzor in advance (1 year in advance) of the termination of the supply of the medicinal product. In November 2022, Novo Nordisk announced to RZN that it plans to supply Ozempic until December 2023. In general, the company did not announce about its exit from the Russian market.

Ozempic (active ingredient – semaglutide) is a hypoglycemic drug that is indicated for use in adult patients with type 2 diabetes on the background of diet and exercise to improve glycemic control and can be used as monotherapy or in combination with other hypoglycemic drugs.

It should be noted that according to the state register, semaglutide preparations are represented on the market only by the trade names Ozempic and Rebelsas. Both drugs are manufactured by Novo Nordisk.

Since 2022, Ozempic has been included in the list of vital and essential drugs (VED) – a list of drugs approved by the Government of the Russian Federation for the purpose of state regulation of prices for medicines. The maximum selling price for the drug Semaglutide, according to the state register, is 5.8 thousand rubles, and the maximum retail price should not exceed 7.7 thousand rubles, including VAT.

However, in November 2022, in the news columns of many online resources, at least two times the maximum registered price of Ozempic was noted in some pharmacies. According to RBC, the drug semaglutide was available in “Europharm” and “LekarPharma” for 16 thousand rubles.

At the same time, pharmacies offered in the application of the federal system of mandatory labeling “Chestniy Znack” (in the chains “Stolichki”, “Neo-Pharm” and “Pharmacy A.v.e”) do not have this drug.


  1. https://tass.ru/obschestvo/17368215
  2. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=55719401-39c2-401b-ade5-5622d7b053c3
  3. https://grls.rosminzdrav.ru/PriceLims.aspx
  4. https://www.rbc.ru/newspaper/2022/11/16/637228a29a7947738ee1838d